Live
- PM Modi lands in Guwahati to kickstart poll campaign
- ‘100 day action plan’ is PM Modi’s signature style for setting goals and meeting targets
- BJP will change the Constitution if they come to power again, says Priyanka Gandhi
- BJP-led NDA to cross 390-mark in Lok Sabha polls, predicts India TV-CNX survey
- Haier launches new TV series in four sizes in India
- Anantapur SP leads joint operation with Karnataka police on illicit liquor
- India to add 13,000 km of new highways in 2024-25: ICRA report
- Salman Khan case: 2 shooters nabbed from Pakistan-bordering Kachchh, sent to 10-day police custody
- Astronomers discover Milky Way's heaviest known black hole
- Jupally helds a Road Show along with Mallu Ravi
Theranostics Offers New Hope to Prostate Cancer Patients
Highlights
Timely diagnosis is crucial to establish the most effective line of treatment in cancers of prostate and neuroendocrine tumor. Now advances in science have made this possible.
Timely diagnosis is crucial to establish the most effective line of treatment in cancers of prostate and neuroendocrine tumor. Now advances in science have made this possible.
Theranostics is a powerful new technique, which blends both diagnostics and therapy, and comes as an highly effective method of treatment of patients suffering from prostate cancer and neuroendocrine tumors, experts at country’s premier Rajiv Gandhi Cancer Institute & Research Centre (RGCI&RC) informed Monday.
Specialist doctors from across the globe came together at a Symposium organized by RGCI & RC on Theranostics of Neuroendocrine Tumors and Prostate Cancers and deliberated how this advance in technology can be used more effectively to treat cancer.
“The field of Theranostics is rapidly facilitating the shift from ‘trial and error’ medicine to personalized medicine and holds great promise for improved patient outcomes. This approach has the potential to help improve drug efficacy by understanding how patients react to specific treatments. The precise targeting properties of theranostic technique may also help to improve the safety profile of a drug, minimizing off-target effects to normal tissues, often seen with various chemotherapies,” Dr Partha S Choudhury, Director, Nuclear Medicine, RGCI & RC.
“Theranostics is a combination of diagnostics and therapy. Under this concept the diagnosis and treatment can be done by the same specific drug for that particular tumor. A suitable therapeutic radionuclide like 177-Lu (Lutetium) or 90Y (Yttrium) can be labelled with the receptor expressing radiopharmaceuticals for targeted radionuclide therapy. The radionuclide therapy delivers extremely high specific radiation to the tumor without damaging the normal tissue, thereby minimizing side effects usually associated with cancer treatment,” Dr Choudhury added.
He added that RGCI & RC is among the select few institutions in the country to have successfully started using this technique.
Dr Choudhury also said that from an economic perspective, theranostics can lead to more cost effective and efficient drug programs, guiding pre-clinical drug development or clinical trial eligibility to help maximize the likelihood of successful outcomes.
In this conference, the delegates were given the detailed insight into the specific receptor based imaging of neuroendocrine and prostate tumors in diagnosis, evaluation of treatment response and prognosis. Further, current information on the use of these receptor based therapy with radionuclides, its response and treatment outcomes were also discussed.
Professor Richard Baum, Chairman and Clinical Director THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence Zentralklinik, Bad Berka, Germany shared his vast personal experience on these topics for the first time in the city.
Next Story
ADVERTISEMENT
